Abstract
Abstract 5256: Incidence of squamous cell carcinoma (SCC) in a large screening cohort of monoclonal B-cell lymphocytosis (MBL)
Cancer research (Chicago, Ill.), Vol.82(12_Supplement), pp.5256-5256
06/15/2022
DOI: 10.1158/1538-7445.AM2022-5256
Abstract
Abstract
MBL is a common pre-malignant condition characterized by circulating clonal B-cells with an absolute B-cell count <5x109/L and no lymphadenopathy, organomegaly, or cytopenias. MBL is the precursor to CLL. The incidence of cutaneous SCC in CLL is significantly higher compared to controls. The incidence of SCC in MBLs has not yet been determined. Study participants from the Mayo Clinic Biobank who had no prior history of hematologic malignancy, were 40 years or older, and were Olmsted County residents completed a health questionnaire and provided blood samples between 7/2009 and 12/2020. Stored peripheral blood mononuclear cells were screened for MBL using flow cytometry. We defined three MBL immunophenotypes: CLL-like MBL (CD5+, CD20dim), atypical MBL (CD5+, CD20+), and non-CLL-like MBL (CD5-, CD20+). MBL individuals were also classified by cell count into low-count MBL (LC-MBL) and high-count MBL (HC-MBL), with HC-MBL having a percent clonal B-cell count ≥85%. Data on newly diagnosed SCC was abstracted from the medical records, and prior history of skin cancer before sample collection was ascertained from patient questionnaires. Individuals were followed from sample date to the earliest of SCC, death, loss to follow-up, progression, or 12/31/2020. Cumulative SCC incidence was adjusted for competing risk of death. Cox regression was used to calculate hazard ratios (HR) and 95% confidence intervals (CIs) adjusted for age and sex. A total of 5,470 participants were screened for MBL and included 949 (17%) with LC-MBL, 63 (1%) with HC-MBL, and 4,458 (81%) controls (negative for MBL). Individuals with HC-MBL (median age 75 years) or LC-MBL (median age 73 years) were significantly older (P<0.001) than controls (median age 66 years). There were 41 (65%) males among HC-MBL, 447 (47%) among LC-MBL, and 1,551 (35%) among controls. Prior skin cancer history was highest among HC-MBLs (N=17, 27%) or LC-MBLs (N=236, 25%) compared to controls (N=767, 17%). After a median follow-up of 18 months (range 0-138), 154 of the 5,470 individuals were identified to have incident SCC following MBL screening. At least one SCC was observed in 3 individuals with HC-MBL, 33 individuals with LC-MBL, and 118 controls. The 5- and 10-year cumulative incidence of SCC in individuals with MBLs was 7% and 16%, respectively; control estimates were 4% and 8%, respectively. However, after adjusting for age and sex, we observed no evidence of an association between MBL and risk of incident SCC (HR=0.95, CI=0.65-1.40, P=0.80), nor when we stratified individuals by age or by sex (all P>0.05). In the largest MBL screening cohort to date, individuals with MBL do not have an increased risk of incident SCC compared to controls. In contrast to individuals with CLL, these individuals with screening MBL do not need increased dermatologic examination for skin cancer, which is important given the high prevalence of MBL (18% of the population above age 40).
Citation Format: Ahmed Nadeem Ansari, Sara J. Achenbach, Sameer A. Parikh, Geffen Kleinstern, Aaron D. Norman, Kari G. Rabe, Connie E. Lesnick, Timothy G. Call, Janet E. Olson, James R. Cerhan, Neil E. Kay, Celine M. Vachon, Esteban Braggio, Curtis A. Hanson, Tait D. Shanafelt, Christian L. Baum, Susan L. Slager. Incidence of squamous cell carcinoma (SCC) in a large screening cohort of monoclonal B-cell lymphocytosis (MBL) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5256.
Details
- Title: Subtitle
- Abstract 5256: Incidence of squamous cell carcinoma (SCC) in a large screening cohort of monoclonal B-cell lymphocytosis (MBL)
- Creators
- Ahmed Nadeem Ansari - 1Mayo Clinic, Rochester, MN;Sara J. Achenbach - 1Mayo Clinic, Rochester, MN;Sameer A. Parikh - 1Mayo Clinic, Rochester, MN;Geffen Kleinstern - 1Mayo Clinic, Rochester, MN;Aaron D. Norman - 1Mayo Clinic, Rochester, MN;Kari G. Rabe - 1Mayo Clinic, Rochester, MN;Connie E. Lesnick - 1Mayo Clinic, Rochester, MN;Timothy G. Call - 1Mayo Clinic, Rochester, MN;Janet E. Olson - 1Mayo Clinic, Rochester, MN;James R. Cerhan - 1Mayo Clinic, Rochester, MN;Neil E. Kay - 1Mayo Clinic, Rochester, MN;Celine M. Vachon - 1Mayo Clinic, Rochester, MN;Esteban Braggio - Mayo Clinic HospitalCurtis A. Hanson - 1Mayo Clinic, Rochester, MN;Tait D. Shanafelt - Stanford UniversityChristian L. Baum - 1Mayo Clinic, Rochester, MN;Susan L. Slager - 1Mayo Clinic, Rochester, MN;
- Resource Type
- Abstract
- Publication Details
- Cancer research (Chicago, Ill.), Vol.82(12_Supplement), pp.5256-5256
- DOI
- 10.1158/1538-7445.AM2022-5256
- ISSN
- 1538-7445
- eISSN
- 1538-7445
- Language
- English
- Date published
- 06/15/2022
- Academic Unit
- Epidemiology
- Record Identifier
- 9984368195302771
Metrics
2 Record Views